Compound (LY#) | Percentage of [14C]LY295501 Dose in 0–24 hr Urine: | ||
---|---|---|---|
Mouse | Rat | Monkey | |
295501 (I) | NC | ND | ND |
311235 (II) | 8.37 ± 1.19 | 17.00 ± 2.33 | 4.59 ± 1.00 |
317813 (III) | ND | 4.18 ± 0.80 | 3.04 ± 0.58 |
335937 (IV) | 4.08 ± 0.37 | 9.82 ± 1.88 | 0.32 ± 0.17 |
004892 (V) | NC | 0.10 ± 0.01 | NC |
301226 (VII) | 1.59 ± 0.20 | 1.93 ± 0.31 | 0.81 ± 0.12 |
301202 (VIII) | 1.30 ± 0.41 | 0.53 ± 0.07 | ND |
Unknowns | 8.29 ± 1.62 | 7.88 ± 1.73 | 4.51 ± 2.24 |
Total % dose in fraction: | 23.86 ± 2.91 | 41.44 ± 5.66 | 13.28 ± 3.91 |
An oral dose of 100 mg/kg [14C]LY295501 was given to three groups of two female C3H mice (50 μCi/kg), three male Fischer 344 rats (20 μCi/kg), or three female rhesus monkeys (10 μCi/kg), and urine samples were collected (over dry ice) over 24 hr. Metabolites were profiled by reverse-phase LC with quantitation by radioactivity. Shown is the per cent of dose represented by each metabolite in the 0–24 hr urine fractions ± the standard deviation.
NC, Not calculated (none detected in two of the three samples in this group); ND, None detected (<0.05% of dose).